203 related articles for article (PubMed ID: 15551883)
21. Molecular basis of Trypanosoma cruzi and Leishmania interaction with their host(s): exploitation of immune and defense mechanisms by the parasite leading to persistence and chronicity, features reminiscent of immune system evasion strategies in cancer diseases.
Ouaissi A; Ouaissi M
Arch Immunol Ther Exp (Warsz); 2005; 53(2):102-14. PubMed ID: 15928579
[TBL] [Abstract][Full Text] [Related]
22. A quantitative study of epidermal Langerhans cells in cutaneous leishmaniasis caused by Leishmania tropica.
Meymandi S; Dabiri S; Dabiri D; Crawford RI; Kharazmi A
Int J Dermatol; 2004 Nov; 43(11):819-23. PubMed ID: 15533064
[TBL] [Abstract][Full Text] [Related]
23. Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis.
Silveira FT; Lainson R; De Castro Gomes CM; Laurenti MD; Corbett CE
Parasite Immunol; 2009 Aug; 31(8):423-31. PubMed ID: 19646206
[TBL] [Abstract][Full Text] [Related]
24. Is the in situ inflammatory reaction an important tool to understand the cellular immune response in American tegumentary leishmaniasis?
Morgado FN; Schubach A; Rosalino CM; Quintella LP; Santos G; Salgueiro M; Conceição-Silva F
Br J Dermatol; 2008 Jan; 158(1):50-8. PubMed ID: 17944980
[TBL] [Abstract][Full Text] [Related]
25. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis.
Okwor I; Liu D; Uzonna J
Vaccine; 2009 Apr; 27(19):2554-62. PubMed ID: 19428861
[TBL] [Abstract][Full Text] [Related]
26. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.
Arora SK; Pal NS; Mujtaba S
Exp Parasitol; 2005 Mar; 109(3):163-70. PubMed ID: 15713447
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of immune granuloma formation in a Leishmania braziliensis-induced self-limiting cutaneous infection in the primate Macaca mulatta.
Souza-Lemos C; de-Campos SN; Teva A; Côrte-Real S; Fonseca EC; Porrozzi R; Grimaldi G
J Pathol; 2008 Nov; 216(3):375-86. PubMed ID: 18702174
[TBL] [Abstract][Full Text] [Related]
28. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
29. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
[TBL] [Abstract][Full Text] [Related]
30. Leishmania initially activates but subsequently down-regulates intracellular mitogen-activated protein kinases and nuclear factor-kappaB signaling in macrophages.
Ben-Othman R; Guizani-Tabbane L; Dellagi K
Mol Immunol; 2008 Jun; 45(11):3222-9. PubMed ID: 18406464
[TBL] [Abstract][Full Text] [Related]
31. Experimental cutaneous leishmaniasis. IV. Selective suppression of cell-mediated immunity during the response of guinea-pigs to infection with Leishmania enriettii.
Bryceson AD; Bray RS; Dumonde DC
Clin Exp Immunol; 1974 Feb; 16(2):189-202. PubMed ID: 4619877
[TBL] [Abstract][Full Text] [Related]
32. CD8 cytotoxic T cells in cutaneous leishmaniasis.
Ruiz JH; Becker I
Parasite Immunol; 2007 Dec; 29(12):671-8. PubMed ID: 18042173
[TBL] [Abstract][Full Text] [Related]
33. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
[TBL] [Abstract][Full Text] [Related]
34. The anatomy of mucosal immune responses.
Garside P; Millington O; Smith KM
Ann N Y Acad Sci; 2004 Dec; 1029():9-15. PubMed ID: 15681738
[TBL] [Abstract][Full Text] [Related]
35. The interface between the Leishmania-infected macrophage and the host's immune system.
Russell DG; Medina-Acosta E; Golubev A
Behring Inst Mitt; 1991 Feb; (88):68-79. PubMed ID: 2049048
[TBL] [Abstract][Full Text] [Related]
36. Early infection with Leishmania major restrains pathogenic response to Leishmania amazonensis and parasite growth.
González-Lombana CZ; Santiago HC; Macedo JP; Seixas VA; Russo RC; Tafuri WL; Afonso LC; Vieira LQ
Acta Trop; 2008 Apr; 106(1):27-38. PubMed ID: 18313021
[TBL] [Abstract][Full Text] [Related]
37. Participation of epidermal langerhans cells in human pathology and their potential as targets for drug development: a review of literature.
Ayala-García I; Hernández-Segura AM; Castell-Rodríguez A; Alvarez Pérez SJ; Téllez BH; Ramírez-González MD
Proc West Pharmacol Soc; 2005; 48():13-20. PubMed ID: 16416652
[TBL] [Abstract][Full Text] [Related]
38. The scavenger receptor MARCO is involved in Leishmania major infection by CBA/J macrophages.
Gomes IN; Palma LC; Campos GO; Lima JG; DE Almeida TF; DE Menezes JP; Ferreira CA; Santos RR; Buck GA; Manque PA; Ozaki LS; Probst CM; DE Freitas LA; Krieger MA; Veras PS
Parasite Immunol; 2009 Apr; 31(4):188-98. PubMed ID: 19292770
[TBL] [Abstract][Full Text] [Related]
39. Role of sand fly saliva in human and experimental leishmaniasis: current insights.
Andrade BB; de Oliveira CI; Brodskyn CI; Barral A; Barral-Netto M
Scand J Immunol; 2007; 66(2-3):122-7. PubMed ID: 17635789
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example.
Bogdan C
Cell Microbiol; 2008 Jun; 10(6):1221-34. PubMed ID: 18363880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
